Shares of Atara Biotherapeutics (NASDAQ:ATRA) reached a new 52-week high and low during mid-day trading on Monday . The stock traded as low as $53.50 and last traded at $53.55, with a volume of 71480 shares traded. The stock had previously closed at $51.05.
Several analysts recently issued reports on ATRA shares. Jefferies Group increased their target price on Atara Biotherapeutics from $30.00 to $46.00 and gave the stock a “buy” rating in a research report on Monday, March 5th. Citigroup cut Atara Biotherapeutics from a “neutral” rating to a “sell” rating in a research report on Thursday, February 15th. JPMorgan Chase started coverage on Atara Biotherapeutics in a research report on Tuesday, April 10th. They set an “overweight” rating and a $56.00 target price for the company. BidaskClub upgraded Atara Biotherapeutics from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, January 23rd. Finally, ValuEngine upgraded Atara Biotherapeutics from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Atara Biotherapeutics currently has an average rating of “Buy” and a consensus price target of $42.50.
The firm has a market cap of $2.20 billion, a price-to-earnings ratio of -12.86 and a beta of 2.55.
Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings results on Tuesday, May 8th. The biotechnology company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.92) by ($0.13). research analysts anticipate that Atara Biotherapeutics will post -4.06 earnings per share for the current year.
In other news, CEO Isaac E. Ciechanover sold 8,700 shares of the firm’s stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $45.28, for a total value of $393,936.00. Following the completion of the sale, the chief executive officer now directly owns 812,613 shares of the company’s stock, valued at approximately $36,795,116.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Mitchall G. Clark sold 25,860 shares of the firm’s stock in a transaction that occurred on Friday, May 18th. The shares were sold at an average price of $50.03, for a total value of $1,293,775.80. Following the completion of the sale, the executive vice president now directly owns 107,972 shares of the company’s stock, valued at $5,401,839.16. The disclosure for this sale can be found here. Insiders have sold a total of 170,371 shares of company stock valued at $7,408,436 in the last 90 days. 10.60% of the stock is currently owned by company insiders.
Several large investors have recently bought and sold shares of the company. Principal Financial Group Inc. bought a new stake in shares of Atara Biotherapeutics in the 1st quarter valued at approximately $214,000. PointState Capital LP bought a new stake in shares of Atara Biotherapeutics in the 1st quarter valued at approximately $11,583,000. California State Teachers Retirement System lifted its stake in shares of Atara Biotherapeutics by 18.9% in the 1st quarter. California State Teachers Retirement System now owns 50,110 shares of the biotechnology company’s stock valued at $1,954,000 after purchasing an additional 7,951 shares during the last quarter. Redmile Group LLC lifted its stake in shares of Atara Biotherapeutics by 50.4% in the 1st quarter. Redmile Group LLC now owns 4,236,017 shares of the biotechnology company’s stock valued at $165,205,000 after purchasing an additional 1,420,029 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its stake in shares of Atara Biotherapeutics by 13.3% in the 1st quarter. The Manufacturers Life Insurance Company now owns 24,505 shares of the biotechnology company’s stock valued at $955,000 after purchasing an additional 2,881 shares during the last quarter.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.